Search

Kymera Therapeutics Inc

Fermé

SecteurSoins de santé

117.35 3.11

Résumé

Variation du prix de l'action

24h

Actuel

Min

111.89

Max

117.97

Chiffres clés

By Trading Economics

Revenu

8M

-61M

Ventes

31M

65M

BPA

-0.62

Marge bénéficiaire

-94.171

Employés

273

EBITDA

6M

-61M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+14.78% upside

Dividendes

By Acuity

Prochains Résultats

3 nov. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

777M

9B

Ouverture précédente

114.24

Clôture précédente

117.35

Kymera Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 août 2026, 20:06 UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

12 août 2026, 20:01 UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

6 août 2026, 19:56 UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5 août 2026, 20:02 UTC

Social Media
News

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4 août 2026, 20:04 UTC

Correlated Moves

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3 août 2026, 19:46 UTC

News

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31 juil. 2026, 20:06 UTC

Correlated Moves

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30 juil. 2026, 19:39 UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29 juil. 2026, 19:32 UTC

Macro Event

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28 juil. 2026, 17:42 UTC

News
Social Media

Shares lower despite Guggenheim's price target increase to $135.

27 juil. 2026, 21:03 UTC

News

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24 juil. 2026, 18:46 UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21 juil. 2026, 19:16 UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20 juil. 2026, 22:16 UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Comparaison

Variation de prix

Kymera Therapeutics Inc prévision

Objectif de Prix

By TipRanks

14.78% hausse

Prévisions sur 12 Mois

Moyen 131.33 USD  14.78%

Haut 155 USD

Bas 112 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

18 ratings

16

Achat

2

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
help-icon Live chat